» Articles » PMID: 30889188

Cost-effectiveness of Financial Incentives for Improving Diet and Health Through Medicare and Medicaid: A Microsimulation Study

Overview
Journal PLoS Med
Specialty General Medicine
Date 2019 Mar 20
PMID 30889188
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Economic incentives through health insurance may promote healthier behaviors. Little is known about health and economic impacts of incentivizing diet, a leading risk factor for diabetes and cardiovascular disease (CVD), through Medicare and Medicaid.

Methods And Findings: A validated microsimulation model (CVD-PREDICT) estimated CVD and diabetes cases prevented, quality-adjusted life years (QALYs), health-related costs (formal healthcare, informal healthcare, and lost-productivity costs), and incremental cost-effectiveness ratios (ICERs) of two policy scenarios for adults within Medicare and Medicaid, compared to a base case of no new intervention: (1) 30% subsidy on fruits and vegetables ("F&V incentive") and (2) 30% subsidy on broader healthful foods including F&V, whole grains, nuts/seeds, seafood, and plant oils ("healthy food incentive"). Inputs included national demographic and dietary data from the National Health and Nutrition Examination Survey (NHANES) 2009-2014, policy effects and diet-disease effects from meta-analyses, and policy and health-related costs from established sources. Overall, 82 million adults (35-80 years old) were on Medicare and/or Medicaid. The mean (SD) age was 68.1 (11.4) years, 56.2% were female, and 25.5% were non-whites. Health and cost impacts were simulated over the lifetime of current Medicare and Medicaid participants (average simulated years = 18.3 years). The F&V incentive was estimated to prevent 1.93 million CVD events, gain 4.64 million QALYs, and save $39.7 billion in formal healthcare costs. For the healthy food incentive, corresponding gains were 3.28 million CVD and 0.12 million diabetes cases prevented, 8.40 million QALYs gained, and $100.2 billion in formal healthcare costs saved, respectively. From a healthcare perspective, both scenarios were cost-effective at 5 years and beyond, with lifetime ICERs of $18,184/QALY (F&V incentive) and $13,194/QALY (healthy food incentive). From a societal perspective including informal healthcare costs and lost productivity, respective ICERs were $14,576/QALY and $9,497/QALY. Results were robust in probabilistic sensitivity analyses and a range of one-way sensitivity and subgroup analyses, including by different durations of the intervention (5, 10, and 20 years and lifetime), food subsidy levels (20%, 50%), insurance groups (Medicare, Medicaid, and dual-eligible), and beneficiary characteristics within each insurance group (age, race/ethnicity, education, income, and Supplemental Nutrition Assistant Program [SNAP] status). Simulation studies such as this one provide quantitative estimates of benefits and uncertainty but cannot directly prove health and economic impacts.

Conclusions: Economic incentives for healthier foods through Medicare and Medicaid could generate substantial health gains and be highly cost-effective.

Citing Articles

Astaxanthin in cancer therapy and prevention (Review).

Copat C, Favara C, Tomasello M, Sica C, Grasso A, Dominguez H Biomed Rep. 2025; 22(4):66.

PMID: 40017498 PMC: 11865706. DOI: 10.3892/br.2025.1944.


Connections between redlining, food access, hypertension, diabetes, and obesity in Boston.

Mehrtash F Front Public Health. 2025; 13:1505462.

PMID: 39975789 PMC: 11835869. DOI: 10.3389/fpubh.2025.1505462.


Will a Programmatic Framework Integrating Food Is Medicine Achieve Value on Investment?.

Fredericks L, Thomas O, Imamura A, MacLaren J, McClure A, Khalil J J Gen Intern Med. 2024; .

PMID: 39528722 DOI: 10.1007/s11606-024-09192-w.


Prospects of Food Taxes for Planetary Health: A Systematic Review of Modeling Studies.

Meszaros A, Dosa N, Peterfi A, Horvath K, Szarvas Z, Balogh J Nutr Rev. 2024; 83(3):503-524.

PMID: 39283704 PMC: 11879128. DOI: 10.1093/nutrit/nuae111.


Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: a feasibility clinical trial.

Avesani C, Heimburger O, Rubin C, Sallstrom T, Faxen-Irving G, Lindholm B Am J Clin Nutr. 2024; 120(3):719-726.

PMID: 39032787 PMC: 11393394. DOI: 10.1016/j.ajcnut.2024.06.025.


References
1.
Shah N, Mason J, Kurt M, Denton B, Schaefer A, Montori V . Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. PLoS One. 2011; 6(1):e16170. PMC: 3026790. DOI: 10.1371/journal.pone.0016170. View

2.
Afshin A, Penalvo J, Del Gobbo L, Silva J, Michaelson M, Oflaherty M . The prospective impact of food pricing on improving dietary consumption: A systematic review and meta-analysis. PLoS One. 2017; 12(3):e0172277. PMC: 5332034. DOI: 10.1371/journal.pone.0172277. View

3.
Pignone M, Earnshaw S, Tice J, Pletcher M . Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006; 144(5):326-36. DOI: 10.7326/0003-4819-144-5-200603070-00007. View

4.
Altman D, Frist W . Medicare and Medicaid at 50 Years: Perspectives of Beneficiaries, Health Care Professionals and Institutions, and Policy Makers. JAMA. 2015; 314(4):384-95. DOI: 10.1001/jama.2015.7811. View

5.
. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4):1033-46. PMC: 3609540. DOI: 10.2337/dc12-2625. View